주메뉴 바로가기
서브메뉴 바로가기
본문 바로가기
About Us
CEO Greeting
Vision
History
CI
Location
Business
Business Outline
Vax-NK Platform
Vax-CARs Platform
Vaxleukin-15
R&D
Laboratory
Pipeline
Technology
IR
IR Resource
Public Disclosures
Public Disclosures
PR
Notice
News
Materials
Careers
Talents
Welfare
Recruitment
KOR
ENG
Goldmmune
TEL
menu open
VaxcellBio, Inc.
KOR
ENG
menu close
About Us
CEO Greeting
Vision
History
CI
Location
Business
Business Outline
Vax-NK Platform
Vax-CARs Platform
Vaxleukin-15 for Companion Animals
R&D
Laboratory
Pipeline
Technology
IR
Public Disclosures
Careers
Talents
Welfare
Recruitment
ⓒ VaxCell Biotherapeutics Co., Ltd.
PR
Notice
News
Materials
News
•
홈
> PR >
News
뉴스(이데일리) - 박셀바이오, ‘Vax-NK’ 임상 2a상 환자 절반 등록
관리자
2022. 05. 03. 10:44
ref.
1959
링크 :
https://www.edaily.co.kr/news/read?newsId=03247206632300712&mediaCodeNo=257&OutLnkChk=Y
Prev:
뉴스(K채널) - ‘화순바이오메디컬협’ 출범…백신특구 활성화 온힘
Next:
뉴스(약사공론) - 박셀바이오, 삼성병원·서울대 출원 NK세포 특허 기술이전
List
